4DMedical Limited announced that its CT:VQ™ imaging technology received CE Mark certification for commercial use in the European Union, enabling rapid deployment in one of the largest respiratory imaging markets. CT:VQ™ offers advanced lung function imaging without radiotracers, improving diagnosis and treatment of pulmonary diseases. The company also secured AU$83 million in private placement funding to support growth initiatives, especially its European expansion. With regulatory clearances in both the EU and U.S., 4DMedical aims to broaden adoption of CT:VQ™ in major hospitals and research centers globally.
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
IQSTEL Inc. announced preliminary net revenue of approximately $207 million for the first half of 2026, marking a 59% increase from $130 million in the same period of 2025. The company expects to complete its acquisition of Ultranet this quarter, whi...
The XRP Ledger has surpassed 8 million activated accounts, signaling increased global adoption for sending and managing blockchain assets. This milestone coincides with whale wallets accumulating 70 million XRP in the past week, indicating strong dem...
Chipotle is launching a $1 million burrito giveaway during the international soccer tournament final on July 19. During the second official hydration break, viewers can participate in a game on Chipotle's Instagram by tracking a lemonade-filled cup a...
Synapticure has introduced a virtual ataxia care program to provide specialized neurological care for adults living with ataxias, a group of disorders causing coordination and motor function loss. Partnering with Biogen for awareness, the program off...
